Elaine Quilici

Stephen Rivera, vice president, global technical accounting advisory services and policy, Johnson & Johnson, capitalizes on his lively personality—and a courageous career journey—to bring people together to shape the future of biopharma.

COMPASS Pathways’ CEO, Kabir Nath, has a clear vision for psychedelics—and is leading the way with the company’s focus on psilocybin and efforts to separate the science from the hype.

Christi Shaw, this year’s Healthcare Businesswomen’s Association (HBA) Woman of the Year, stays true to her beliefs—and life mission—of helping others.

Christi Shaw, CEO of Kite, is working hard to bring cell therapy to the masses, fueled by her family’s personal experiences with cancer.

In episode 117, Helen Sabzevari, CEO of Precigen, discusses her drive to study science as a Persian-born woman, the opportunities she’s had to research immunology, and how she’s now developing next-generation CAR-T treatments for cancer, in addition to other therapies.

Use against pair of pathways could pave way for standout in stocked eye disease market.

Pharm Exec releases its annual product launch feature articles.

In episode 116, Dr. Greg Rippon, vice president and chief medical partner at Genentech, discusses his work in Alzheimer’s and his outlook for the future of the therapeutic space.

Marie-France Tschudin, president, innovative medicines international, and chief commercial officer at Novartis, taps into life lessons to help bring therapies to people in novel ways­.

Personalized medicine here to stay after massive uptick in 2021 approvals.

In episode 114, Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses why it’s important to manage high levels of workplace stress, and how companies can help employees in need.

In episode 113, Indranil Bagchi, senior vice president and worldwide head, value and access at Novartis, and member of Pharmaceutical Executive Editorial Advisory Board, discusses the challenges of reaching patients and what he believes can help improve the situation.

Pharm Exec introduces new members to EAB.

In episode 112, Nima Farzan, CEO of Kinnate, who was one of Pharmaceutical Executive’s Emerging Pharma Leaders in 2013, discusses how he’s successfully navigated his career path, from building a foundation in pharma to growing his expertise in biotech.

A flurry of new titles entering the executive ranks has its pros and cons.

Tremeau CEO Bradford Sippy strikes a new chord with revival of old blockbuster drug—modifying it as a unique treatment for orphan hemophilia condition.

Tips for surviving a shift in executive roles.

Pharma workforce shifting amidst rise of technology in healthcare.

Ken Winell, chief technology officer of Greater Than One, talks about the metaverse and the potential it has to serve the pharma industry.

Myrto Kontaxi, a partner in the Biopharma Sustainability Roundtable, and lead author on its updated Biopharma Investor ESG Communications Guidance; and Victoria Emerick, global head of sustainability strategy and operations at Bristol Myers Squibb, a Biopharma Sustainability Roundtable participant, and a key contributor to the Guidance development process, discuss the growing demand for better communication about ESG strategy and performance, and how the updated ESG Guidance can help both biopharma companies and investors respond.

Using edutainment to capture audiences and break down complex medical information.

‘Whole self’ approach to life and leadership keys passion for helping patients.

Pharm Exec announces annual Emerging Pharma Leaders class.

In episode 107, Camille Hertzka, VP, head of oncology US medical at AstraZeneca, talks about her experience as a leader in oncology over the years and to expect from the space moving into the future.

Pharm Exec introduces new monthly columns.

In episode 104, Susanne Schaffert, president of Novartis Oncology, discusses her career journey, which has combined both a passion for the arts and science, and how she believes the two can work together in pharma.

A look at the renewed efforts of biopharma companies in exploring age-old substances to treat mental health conditions and more, minus the negative effects.

For pharma teams, reaping the talent benefits requires skillful oversight.

Prior experiences in pharma and handling of opioid epidemic offer valuable lessons.

In episode 103, Robert Clarke, CEO and co-founder of Kinaset Therapeutics, talks about developing inhaled therapies to fight asthma and COPD, which is especially relevant as COVID-19 poses significant problems for sufferers.